Compare CNF & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNF | FLNA |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | China | United States |
| Employees | N/A | 20 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.8M | 61.8M |
| IPO Year | 2018 | N/A |
| Metric | CNF | FLNA |
|---|---|---|
| Price | $2.86 | $1.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.1K | ★ 333.5K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $252.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $1.15 |
| 52 Week High | $24.00 | $2.03 |
| Indicator | CNF | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.22 | 39.31 |
| Support Level | $2.57 | $1.16 |
| Resistance Level | $3.60 | $1.80 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 10.00 | 12.86 |
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, the group generates all of its revenues in the PRC.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.